Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN®/XIFAXAN®) 550 mg

NCT02488993 is registered in ClinicalTrials.gov with Norgine as lead sponsor.

NCT NCT02488993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02488993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN®/XIFAXAN®) 550 mg
Lead sponsor
Norgine
Phase
Observational
Overall status
Completed
Start date
June 30, 2015
Completion date
September 29, 2018
Enrollment
389 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic encephalopathy